T2 Biosystems (NASDAQ:TTOO) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a research note issued on Friday. The firm set a “sell” rating on the medical equipment provider’s stock.

T2 Biosystems Stock Performance

TTOO opened at $0.35 on Friday. T2 Biosystems has a 1-year low of $0.31 and a 1-year high of $8.38. The company’s fifty day moving average price is $0.73 and its two-hundred day moving average price is $2.77.

Hedge Funds Weigh In On T2 Biosystems

A hedge fund recently bought a new stake in T2 Biosystems stock. Armistice Capital LLC acquired a new position in T2 Biosystems, Inc. (NASDAQ:TTOO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned about 9.49% of T2 Biosystems as of its most recent SEC filing. 23.18% of the stock is owned by institutional investors.

T2 Biosystems Company Profile

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.